TY - JOUR
T1 - Findings from the Morquio A Registry Study (MARS) after 6 years
T2 - Long-term outcomes of MPS IVA patients treated with elosulfase alfa
AU - Mitchell, John J.
AU - Burton, Barbara K.
AU - Bober, Michael B.
AU - Campeau, Philippe M.
AU - Cohen, Shelda
AU - Dosenovic, Sara
AU - Ellaway, Carolyn
AU - Bhattacharya, Kaustuv
AU - Guffon, Nathalie
AU - Hinds, David
AU - Lail, Alice
AU - Lin, Shuan Pei
AU - Magner, Martin
AU - Raiman, Julian
AU - Schwartz-Sagi, Liat
AU - Stepien, Karolina M.
N1 - Funding Information:
This work was supported by BioMarin Pharmaceutical, Inc.The authors wish to thank all MARS investigators for their contribution to this study. They are also grateful to Ismar Healthcare NV and Abigail Hunt (BioMarin Pharmaceutical) for their assistance in the writing of this manuscript, which was funded by BioMarin Pharmaceutical Inc. Novato, CA, USA. In addition, they wish to thank Anita Hsieh (McGill University Health Centre, Montreal, Quebec, Canada) and all of the MARS study coordinators.
Funding Information:
This work was supported by BioMarin Pharmaceutical, Inc .
Publisher Copyright:
© 2022 The Authors
PY - 2022/9/1
Y1 - 2022/9/1
N2 - Background: The Morquio A Registry Study (MARS) is an ongoing, multinational, observational study of patients with MPS IVA. Key objectives of MARS are to characterize the heterogeneity and natural history of disease and to evaluate long-term effectiveness and safety of elosulfase alfa enzyme replacement therapy (ERT). Enrollment began in September 2014; data on medical history, clinical outcomes, and safety assessments are collected as part of routine care. Results: As of February 2021, 381 subjects from 17 countries had enrolled in MARS: 58 ERT-naïve subjects and 323 ERT-treated subjects (≥1 infusion), with a mean ERT exposure of 5.5 years (SD 2.8) and median age at first ERT treatment of 9.8 years. ERT-treated subjects were younger at diagnosis (median 3.4 vs 6.5 years) relative to ERT-naïve subjects. Among ERT-treated subjects, urinary keratan sulfate (uKS) levels declined from pre-ERT baseline to last follow-up on treatment (mean % change [95% confidence interval]: −52.5% [−57.5%, −47.4%]; n = 115) and 6-min walk test distance remained stable (mean change: −6.1 [−27.6, 15.5] m; n = 131) over a mean follow-up of 5.5 years. Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) increased in subjects who were < 18 years of age at ERT initiation (mean change: +0.3 [0.1, 0.4] L and + 0.4 [0.3, 0.5] L; mean follow-up: ∼6 years; n = 82) and were stable in subjects ≥18 years (mean change: 0.0 [−0.0, 0.1] L and 0.0 [−0.1, 0.1] L; mean follow-up: 4.6 years; n = 38). Overall, 148 (47.1%) ERT-treated subjects experienced ≥1 adverse event (AE) and 110 subjects (35%) reported ≥1 serious AE. Drug-related AEs were reported in 39 (12.4%) subjects; the most common were hypersensitivity (9 subjects [2.9%]), urticaria (8 subjects [2.5%]), and pyrexia (7 subjects [2.2%]). Conclusions: MARS is the longest and largest observational study of MPS IVA patients to date, with a heterogenous population that is representative of the MPS IVA population overall. Data collected over the first 6 years of MARS provide real-world evidence for long-term stabilization of endurance and respiratory function among ERT-treated patients, with no new safety concerns identified.
AB - Background: The Morquio A Registry Study (MARS) is an ongoing, multinational, observational study of patients with MPS IVA. Key objectives of MARS are to characterize the heterogeneity and natural history of disease and to evaluate long-term effectiveness and safety of elosulfase alfa enzyme replacement therapy (ERT). Enrollment began in September 2014; data on medical history, clinical outcomes, and safety assessments are collected as part of routine care. Results: As of February 2021, 381 subjects from 17 countries had enrolled in MARS: 58 ERT-naïve subjects and 323 ERT-treated subjects (≥1 infusion), with a mean ERT exposure of 5.5 years (SD 2.8) and median age at first ERT treatment of 9.8 years. ERT-treated subjects were younger at diagnosis (median 3.4 vs 6.5 years) relative to ERT-naïve subjects. Among ERT-treated subjects, urinary keratan sulfate (uKS) levels declined from pre-ERT baseline to last follow-up on treatment (mean % change [95% confidence interval]: −52.5% [−57.5%, −47.4%]; n = 115) and 6-min walk test distance remained stable (mean change: −6.1 [−27.6, 15.5] m; n = 131) over a mean follow-up of 5.5 years. Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) increased in subjects who were < 18 years of age at ERT initiation (mean change: +0.3 [0.1, 0.4] L and + 0.4 [0.3, 0.5] L; mean follow-up: ∼6 years; n = 82) and were stable in subjects ≥18 years (mean change: 0.0 [−0.0, 0.1] L and 0.0 [−0.1, 0.1] L; mean follow-up: 4.6 years; n = 38). Overall, 148 (47.1%) ERT-treated subjects experienced ≥1 adverse event (AE) and 110 subjects (35%) reported ≥1 serious AE. Drug-related AEs were reported in 39 (12.4%) subjects; the most common were hypersensitivity (9 subjects [2.9%]), urticaria (8 subjects [2.5%]), and pyrexia (7 subjects [2.2%]). Conclusions: MARS is the longest and largest observational study of MPS IVA patients to date, with a heterogenous population that is representative of the MPS IVA population overall. Data collected over the first 6 years of MARS provide real-world evidence for long-term stabilization of endurance and respiratory function among ERT-treated patients, with no new safety concerns identified.
KW - Elosulfase alfa
KW - Morquio A syndrome
KW - enzyme replacement therapy
KW - mucopolysaccharidosis IVA
KW - registry
UR - http://www.scopus.com/inward/record.url?scp=85137396863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137396863&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2022.08.007
DO - 10.1016/j.ymgme.2022.08.007
M3 - Article
C2 - 36087504
AN - SCOPUS:85137396863
SN - 1096-7192
VL - 137
SP - 164
EP - 172
JO - Biochemical Medicine and Metabolic Biology
JF - Biochemical Medicine and Metabolic Biology
IS - 1-2
ER -
